Biotechnology

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 10076

Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award

LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categ...

2021-10-04 15:00 1437

World's Leading Neuroscientists Unveil Research on COVID-19's Impact on the Brain, Understanding Migraine Pathophysiology, Solving the Mystery of Sleep, Biomarkers in Traumatic Brain Injury and More at 25th Biennial World Congress of Neurology from October 3-7

LONDON, Oct. 2, 2021 /PRNewswire/ -- The impact COVID-19 has on the brain, understanding migraine pathophysiology, solving the mystery of sleep by "Lighting Up the Brain," blood biomarkers for traumatic brain injury and more groundbreaking research will be unveiled by the world's leading neurosci...

2021-10-02 12:10 4536

CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021

* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...

2021-10-02 08:30 9239

TurtleTree Launches New Research and Development Facility in Greater Sacramento

WEST SACRAMENTO, Calif., Oct. 2, 2021 /PRNewswire/ -- TurtleTree has officially opened its new R&D facility inCalifornia's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and ...

2021-10-01 22:00 2975

I-Mab Announces Upcoming Participation at October Conferences

SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...

2021-10-01 20:00 14432

Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs

SINGAPORE and SYDNEY, Oct. 1, 2021 /PRNewswire/ -- Medidata, a Dassault Systèmes company, recently namedRama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veteran...

2021-10-01 09:00 3051

Binhai sets ambitious biomedical goals with support of key companies

TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...

2021-10-01 01:08 1564

Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- RVAC Medicines  Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company inSingapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the to...

2021-10-01 00:50 1949

CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies

HONG KONG, Sept. 30, 2021 /PRNewswire/ -- CBMG Holdings (or the "Company"), a Cayman Island biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer and degenerative diseases, today announced the closing of a $120 million Series A investment, led by As...

2021-09-30 22:06 3362

Cynata Enters into a New Strategic Partnership with Fujifilm

Key highlights * Cynata and Fujifilm have entered into a new strategic partnership which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus™ therapeutic mesenchymal stem cell (MSC) products * Cyn...

2021-09-30 21:30 2535

Benson Hill Completes Business Combination with Star Peak Corp II

Creates a leading publicly traded sustainable food technology company developing better tasting, more nutritious, sustainable and affordable ingredient and food choices CropOS® technology platform empowers the Company to bring seed to fork innovations to fuel the rapidly growing plant-based food...

2021-09-30 20:01 22397

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021The current U.S. NHL clinical trial has now expanded to include clinical sites inChina as an international multi-center clinical trial, which will potentially lead to a r...

2021-09-30 20:00 6280

Broncus Completed the First-in-man Clinical Trial of Its Targeted Lung Denervation Radiofrequency Ablation System

HONG KONG, Sept. 30, 2021 /PRNewswire/ -- Broncus Holding Corporation ("Broncus" or the "Company") is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chroni...

2021-09-30 19:40 2390

Zantrene® kills melanoma cancer cells that overproduce FTO

* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells * Results are highly supportive of future clinical trials in ...

2021-09-30 11:58 10187

GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor

GUANGZHOU, China, Sept. 29, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...

2021-09-30 08:05 1860

Recbio and Rhegen Signed an mRNA Vaccine Cooperation Agreement

TAIZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (referred to as "Recbio") and Shenzhen Rhegen Biotechnology Co., Ltd. (referred to as "Rhegen Bio") recently signed a joint venture agreement to establish a joint venture company "Wuhan Rhecogen Biotechnology Co., ...

2021-09-29 19:37 2783

Hong Kong's first biotech firm to cultivate microalgae for its abundant plant-based protein for consumer application

HONG KONG, Sept. 29, 2021 /PRNewswire/ -- The bioscience start-up, Geb Impact Technology Company Limited has developed an advanced technology to rapidly cultivate clear water single-celled microalgae. Microalgae are the abundant and sustainable source of high-quality plant-based protein, fit for ...

2021-09-29 18:26 2216

Reversing Asia Pacific's biodiversity and nature loss crisis could result in US$4.3 trillion worth of nature-positive business opportunities

* A new study by AlphaBeta, Temasek and the World Economic Forum estimates that 63 percent ofAsia Pacific's GDP, US$19.5 trillion, is threatened by biodiversity and nature loss * It also identifies 59 nature-positive business opportunities that can unlock US$4.3 trillion in business value and ...

2021-09-29 15:36 3293

Molecular Stethoscope, Inc. Announces Presentation at 16th Annual Sequencing to Function: Analysis and Applications for the Future Meeting

Presentation highlights a path forward to lead the development of the Company's clinical-grade Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform PALO ALTO, Calif., Sept. 29, 2021 /PRNewswire/ -- Molecular Stethoscope, Inc., a Precision Medicine biotechnology compa...

2021-09-29 15:00 1644
1 ... 217218219220221222223 ... 307

Week's Top Stories